冠脉内支架临床发展策略

冠脉内支架是临床上预防ＰＴＣＡ并发症的有效措施，但金属支架固有的血栓菜成原性和对血管壁组织的永久性刺激可导致院内心脏事件和再狭窄。为解决上述问题，作者提出，血管内支架联合靶向药物传输离子照射或基因治疗、基因修饰的内皮细胞的种植支架、吱物可吸收缓释药物支架材料研制为临床冠脉内支架开辟了广阔的发展前景。

Clinical Strategies for Development of Intracoronary Stents

Intracoronary stenting is an effective measure to prevent PTCA-associated complications in clinicalpractice,appearing to be superior to all other interventional techniques. However,the intrinsic thrombogenicity andpermanent stimulation to injured vessel wall tissue of all the current available metallic stents may result in inhospitalevents such as thrombosis, (sub)acute coronary closure,emergency bypass surgery,hemorrhagic complications,pseudoaneurysm,or even vessel per foration),and restenosis. In order to settle the above-mentioned problems, theauthors point out that intravascular stenting in combination with target drug delivery,or ionic radiation,or genetherapy (direct gene transfer,antisense oligodeoxynucleotides,etc ); seeding of genetically reformed endothelial cellson metallic stents; study and development of new materials for biodegradable stents,controlled drug release system;temporary metallic stents land locally site-specific drug delivery system take facilitated new clinical strategiesfor the development of intracoronary stents.